Crystagen

Crystagen is a short synthetic peptide from the Russian 'Khavinson' bioregulator family, marketed for the immune system. In a lab study of aging spleen cells, it activated B-cells, the immune cells that make antibodies, though unlike some peptides tested it didn't drive new cell growth as the spleen aged. The research is Russian-led, preclinical, hasn't been independently replicated in the West, there are no human trials, and Crystagen isn't FDA-approved.

Crystagen is marketed as an immune-system "bioregulator." In a lab study of aging spleen cells, it activated B-cells (antibody-producing immune cells), though — unlike some peptides tested — it did not drive cell renewal as the spleen aged. This fits a broad tissue-specific peptide theory but is a laboratory finding; there are no large controlled human trials showing Crystagen treats any condition.

Not a drug in the US and not FDA-approved for any indication. A synthetic "Khavinson" short-peptide bioregulator ("cytogen") from the St. Petersburg Institute of Bioregulation and Gerontology (Russia), associated with the immune system. Evidence is almost entirely preclinical (cell) plus small Russian studies; no large controlled human trials. WADA: not specifically named; best treated as S0 (non-approved), prohibited at all times — verify with your anti-doping organization. Not DEA-scheduled.

Crystagen has essentially no controlled human safety data and is not FDA-approved. It is not a treatment for any immune condition. As a non-approved research peptide it is best treated as prohibited in regulated sport (WADA S0). VialWise is a research and educational reference, not medical advice.

⚠️ For research and educational purposes only. Crystagen is not FDA-approved and is not a treatment for any immune or other condition. Its evidence is preclinical. Information here is informational, not medical advice.

⚠️ Part of the Khavinson "bioregulator" family — read the shared caveat. Crystagen is one of a set of short peptides from the St. Petersburg Institute of Bioregulation and Gerontology, sharing a thin, mostly-preclinical, largely single-institute evidence base and no large controlled human trials.[²]

Crystagen is a synthetic short peptide in the "Khavinson" bioregulator family, associated with the immune system. According to PubMed, a study of Khavinson peptides in aging spleen reported that Crystagen activated B-cells (the immune cells that produce antibodies); notably, unlike some other peptides tested, Crystagen did not cause cell renewal in the aging spleen.[¹] This underpins its marketing as an immune peptide under the Khavinson tissue-specific theory.[²]

Evidence quality. Preclinical (cell). No large controlled human trials. See the shared Khavinson caveat below.

### About the Khavinson bioregulators (shared framing)

Developed from the 1970s by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, these cytomedin/cytogen peptides went from organ-extract complexes to synthetic short peptides proposed to have tissue-specific effects under a "peptide theory of ageing."[²] Honest caveats: evidence is overwhelmingly preclinical plus small, often non-blinded Russian studies; no large independent randomized trials; none FDA-approved; sold in Russia as injectables and supplements.

Regulatory status (US). Not FDA-approved; not a drug. Not DEA-scheduled.

Regulatory status (sport — WADA). Not specifically named; best treated as S0 (non-approved), prohibited at all times. Verify with your anti-doping organization.

Common research interests. Immune support (its associated system). Extrapolated from preclinical data, not an established human use.

Commonly reported

• Injection-site reactions
• Reactions to research-supply material of variable purity
• Immune modulation. Crystagen activates B-cells in vitro;[¹] consequences of modulating immunity in humans are uncharacterized.
• Unknown long-term safety.

Not a treatment for any immune condition — see a clinician

Autoimmune disease / immunosuppression — caution given the immune-modulating signal

Pregnancy and lactation — no data; default to contraindicated

Pediatric use — no data; not for researchers under 18

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; not DEA-scheduled.

Regulatory note (sport): Best treated as WADA S0. Verify with your anti-doping organization.

Bioregulator (Khavinson peptide)

A very short synthetic peptide from the St. Petersburg Institute of Bioregulation and Gerontology, each linked to a tissue — here, the immune system.

B-cell

An immune cell that makes antibodies. Crystagen activated these in the lab.

Spleen

An immune organ; the tissue used in the Crystagen study.

Preclinical

Research in cells or animals, before human testing.

1. Chervyakova NA, Linkova NS, Chalisova NI, Koncevaya EA, Trofimova SV, Khavinson VKh. (2014). [Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process]. Advances in Gerontology (Uspekhi Gerontologii), 27(1):224–228.(PMID 28976144)
2. Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters, 23 Suppl 3:11–144.(PMID 12374906)

• Bronchogen — same mechanism class
• Cardiogen — same mechanism class
• Cartalax — same mechanism class
• Chonluten — same mechanism class
• Cortagen — same mechanism class
• Epitalon — same mechanism class